Qiming Venture Partners

Qiming Venture Partners is a venture capital firm.

LongBio Pharma, a Qiming Venture Partners portfolio company developing innovative drugs for allergic and autoimmune diseases, lists on the Hong Kong Stock Exchange on June 5, 2026, Beijing time. The company (01779.HK) issues shares at HK$6.06 each and opens at HK$44.30, with a market capitalization of HK$0.7 billion; the listing marks Qiming Venture Partners’ seventh IPO of the year.

Jun 2026 · PR NewswireNews article

Qiming Venture Partners managing partner Alex Zhou ranks 80th on the 2026 Forbes Midas List, which recognizes his early investments in Chinese AI and semiconductor companies. Forbes cites investments including Biren Technology and Zhipu AI, identifying Zhou’s bets in both fields as the basis for his placement.

May 2026 · Qiming Venture PartnersNews article

Qiming Venture Partners opened its 2026 Healthcare PhD Summer Internship on May 11, 2026, placing doctoral candidates from top U.S. and U.K. universities on its healthcare investment team. The eight-to-ten-week program spans biotech, medtech, and AI healthcare.

May 2026 · Qiming Venture PartnersNews article

Alamar Biosciences begins trading on Nasdaq on April 17, 2026, under ticker ALMR, with an opening market capitalization near $1.5 billion. Qiming Venture Partners identifies Alamar as a portfolio company and says it backed the precision-proteomics company from its 2020 Series A round, holding roughly 19% before the offering.

Apr 2026 · Qiming Venture PartnersNews article